The therapeutic efficacy of Gliclazide can be increased when used in combination with Acetazolamide. The therapeutic efficacy of Gliclazide can be increased when used in combination with Acenocoumarol. The protein binding of Gliclazide can be decreased when combined with Acemetacin. The protein binding of Gliclazide can be decreased when combined with Aceclofenac. The therapeutic efficacy of Gliclazide can be increased when used in combination with Acebutolol. The risk or severity of hypoglycemia can be increased when Acarbose is combined with Gliclazide. The metabolism of Abrocitinib can be decreased when combined with Gliclazide. The metabolism of Gliclazide can be increased when combined with Abatacept. The therapeutic efficacy of Gliclazide can be decreased when used in combination with Abaloparatide. The presence of this polymorphism in CYP2C19 is associated with reduction in gliclazide metabolism. Type Small Molecule Groups Approved Structure

Gliclazide is extensively metabolized by the liver its metabolites are excreted in both urine (60-70%) and feces (10-20%). Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. Sulfonylureas are associated with weight gain, though less so than insulin. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release.

2, 3 Gliclazide belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. 1 On the other hand, based on the pharmacological efficacy, gliclazide is considered a second-generation sulfonylurea which presents a higher potency and a shorter half-life. It has been classified differently according to its drug properties in which based on its chemical structure, gliclazide is considered a first-generation sulfonylurea due to the structural presence of a sulfonamide group able to release a proton and the presence of one aromatic group. Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Diamicron Generic Name Gliclazide DrugBank Accession Number DB01120 Background

Heparin rob holland